Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain

被引：67
作者：
Hung, Ivan F. N. [1 ,2 ,3 ]
Levin, Yotam
To, Kelvin K. W. [2 ,3 ]
Chan, Kwok-Hung [2 ,3 ]
Zhang, Anna Jinxia [2 ,3 ]
Li, Patrick [2 ,3 ]
Li, Clara [2 ,3 ]
Xu, Ting [2 ,3 ]
Wong, Tin-Yan [2 ,3 ]
Yuen, Kwok-Yung [2 ,3 ]
机构：
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Div Infect Dis, Pokfulam, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infect Dis, Carol Yus Ctr Infect, Pokfulam, Hong Kong, Peoples R China
来源：
VACCINE | 2012年 / 30卷 / 45期
关键词：
Intradermal; Influenza; Vaccine; Immunogenicity; 2009; H1N1; RANDOMIZED CONTROLLED SAFETY; ACUTE MYOCARDIAL-INFARCTION; ANTIBODY-RESPONSE; HEALTHY-ADULTS; ELDERLY PERSONS; UNITED-STATES; VIRUS; TRIAL; HOSPITALIZATIONS; MICROINJECTION;
D O I：
10.1016/j.vaccine.2012.08.014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: We hypothesized that low dose intradermal vaccination of the trivalent influenza vaccine (TIV) delivered by the MicronJet600 (TM) (NanoPass Technologies, Israel) would be non-inferior to the full dose intramuscular and mid dose Intanza (R) vaccination in the elderly and the chronically ill adults. Methods: We performed a prospective randomized trial on elderly and chronically ill adults. Subjects were randomly assigned into 4 groups. Groups ID3 and ID9 received reduced dose ID TIV (3 mu g and 9 mu g of hemagglutinin (HA) per strain respectively) delivered by MicronJet600 (TM) (NanoPass Technologies, Israel). Group INT9 received reduced dose ID TIV (9 mu g) delivered by Becton Dickinson's Soluvia (TM) device (Intanza (R) 9, Sanofi-Pasteur, France). Control group IM15 received a full dose IM TIV (15 mu g). We measured antibody titers by hemagglutination inhibition (HAI) and microneutralization (MN) assays at baseline and day 21. Results: Baseline characteristics for all groups were similar (group and sample sizes: ID3 = 63; ID9 = 68; INT9 = 65; and IM15 = 66). At day 21 post vaccination, the GMT ratio and the seroconversion rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI and MN assays were significantly higher in the ID groups compared with the full dose IM vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly higher in the ID groups when compared with the full dose IM group. Direct comparison among the three ID groups showed no significant differences. No serious adverse events related to vaccination were reported. Conclusion: Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 strain, and according to some measures, for the H3N2 strain. At risk subjects indicated for the TIV should be considered for intradermal immunization to compensate for reduced immunogenicity. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6427 / 6435
页数：9
相关论文
共 31 条
[1]   Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany [J].
Arnou, Robert ;
Frank, Matthias ;
Hagel, Thomas ;
Prebet, Alice .
ADVANCES IN THERAPY, 2011, 28 (07) :555-565
[2]  
Bellei N.C.J., 2006, Braz J Infect Dis, V10, P269, DOI 10.1590/S1413-86702006000400011
[3]   Serum antibody responses after intradermal vaccination against influenza [J].
Belshe, RB ;
Newman, FK ;
Cannon, J ;
Duane, C ;
Treanor, J ;
Van Hoecke, C ;
Howe, BJ ;
Dubin, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) :2286-2294
[4]   Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial [J].
Beran, Jiri ;
Ambrozaitis, Arvydas ;
Laiskonis, Alvydas ;
Mickuviene, Narseta ;
Bacart, Patrick ;
Calozet, Yvan ;
Demanet, Etienne ;
Heijmans, Stephane ;
Van Belle, Paul ;
Weber, Francoise ;
Salamand, Camille .
BMC MEDICINE, 2009, 7
[5]   Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine A randomized study in US adults [J].
Campbell, James D. ;
Chambers, Christopher V. ;
Brady, Rebecca C. ;
Caldwell, Michael C. ;
Bennett, Nathan L. ;
Fourneau, Marc A. ;
Jain, Varsha K. ;
Innis, Bruce L. .
HUMAN VACCINES, 2011, 7 (01) :81-88
[6]   Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza [J].
Chan, Kwok-Hung ;
To, Kelvin K. W. ;
Hung, Ivan F. N. ;
Zhang, Anna J. X. ;
Chan, Jasper F. W. ;
Cheng, Vincent C. C. ;
Tse, Herman ;
Che, Xiao-Yan ;
Chen, Honglin ;
Yuen, Kwok-Yung .
CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (05) :867-873
[7]   Acceptance of IntanzaA® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina [J].
Eizenberg, Peter ;
Booy, Robert ;
Naser, Nadim ;
Mason, Glen ;
Stamboulian, Daniel ;
Weber, Francoise .
ADVANCES IN THERAPY, 2011, 28 (08) :640-649
[8]   Immunogenicity and safety of intradermal influenza vaccine in children [J].
Esposito, Susanna ;
Daleno, Cristina ;
Picciolli, Irene ;
Tagliaferri, Laura ;
Scala, Alessia ;
Prunotto, Giulia ;
Montinaro, Valentina ;
Galeone, Carlotta ;
Principi, Nicola .
VACCINE, 2011, 29 (44) :7606-7610
[9]   The impact of influenza on the health and health care utilisation of elderly people [J].
Fleming, DM ;
Elliot, AJ .
VACCINE, 2005, 23 :S1-S9
[10]   Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults [J].
Frenck, Robert W., Jr. ;
Belshe, Robert ;
Brady, Rebecca C. ;
Winokur, Patricia L. ;
Campbell, James D. ;
Treanor, John ;
Hay, Christine M. ;
Dekker, Cornelia L. ;
Walter, Emmanuel B., Jr. ;
Cate, Thomas R. ;
Edwards, Kathryn M. ;
Hill, Heather ;
Wolff, Mark ;
LeDuc, Tom ;
Tornieporth, Nadia .
VACCINE, 2011, 29 (34) :5666-5674
1234